PL420249A1 - Kompozycja do leczenia czerniaka u ludzi - Google Patents

Kompozycja do leczenia czerniaka u ludzi

Info

Publication number
PL420249A1
PL420249A1 PL420249A PL42024917A PL420249A1 PL 420249 A1 PL420249 A1 PL 420249A1 PL 420249 A PL420249 A PL 420249A PL 42024917 A PL42024917 A PL 42024917A PL 420249 A1 PL420249 A1 PL 420249A1
Authority
PL
Poland
Prior art keywords
composition
melanoma
humans
treatment
aqueous
Prior art date
Application number
PL420249A
Other languages
English (en)
Other versions
PL239178B1 (pl
Inventor
Wojciech PLACHA
Jacek ZAGAJEWSKI
Małgorzata SZCZYGIEŁ
Monika PIWOWAR
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL420249A priority Critical patent/PL239178B1/pl
Priority to EP18742177.1A priority patent/EP3570828B1/en
Priority to US16/479,397 priority patent/US10912756B2/en
Priority to PCT/PL2018/050002 priority patent/WO2018135959A1/en
Publication of PL420249A1 publication Critical patent/PL420249A1/pl
Publication of PL239178B1 publication Critical patent/PL239178B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja zawierająca wodny roztwór taksanu i wodny roztwór simwastatyny do stosowania w leczeniu i zapobieganiu czerniaka u ludzi. Kompozycja charakteryzuje się tym, że taksanem jest paklitaksel lub docetaksel, korzystnie paklitaksel.
PL420249A 2017-01-19 2017-01-19 Kompozycja do leczenia czerniaka u ludzi PL239178B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL420249A PL239178B1 (pl) 2017-01-19 2017-01-19 Kompozycja do leczenia czerniaka u ludzi
EP18742177.1A EP3570828B1 (en) 2017-01-19 2018-01-19 Combination of a taxane and a hydrophobic statin for the treatment of human melanoma
US16/479,397 US10912756B2 (en) 2017-01-19 2018-01-19 Method for the treatment of human melanoma
PCT/PL2018/050002 WO2018135959A1 (en) 2017-01-19 2018-01-19 A composition for the treatment of human melanoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL420249A PL239178B1 (pl) 2017-01-19 2017-01-19 Kompozycja do leczenia czerniaka u ludzi

Publications (2)

Publication Number Publication Date
PL420249A1 true PL420249A1 (pl) 2018-07-30
PL239178B1 PL239178B1 (pl) 2021-11-08

Family

ID=62909239

Family Applications (1)

Application Number Title Priority Date Filing Date
PL420249A PL239178B1 (pl) 2017-01-19 2017-01-19 Kompozycja do leczenia czerniaka u ludzi

Country Status (4)

Country Link
US (1) US10912756B2 (pl)
EP (1) EP3570828B1 (pl)
PL (1) PL239178B1 (pl)
WO (1) WO2018135959A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240336972A1 (en) * 2021-07-30 2024-10-10 Oregon Health & Science University Methods for selecting melanoma patients for therapy and methods of reducing or preventing melanoma metastasis

Also Published As

Publication number Publication date
US20190358194A1 (en) 2019-11-28
EP3570828A4 (en) 2020-11-11
US10912756B2 (en) 2021-02-09
EP3570828A1 (en) 2019-11-27
WO2018135959A1 (en) 2018-07-26
PL239178B1 (pl) 2021-11-08
EP3570828B1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2019012534A (es) Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico.
EP3673905A4 (en) COMPOSITION CONTAINING CANNABIDIOL AND / OR CANNABIDIVARINE AND APPLICATION OF THE COMPOSITION IN THE TREATMENT OF DYSMENORRHEA
MX382339B (es) Inhibidores g12c de kras.
LT3658140T (lt) Aprocitentano ir kitų veikliųjų sudedamųjų dalių deriniai, skirti atsparios hipertenzijos gydymui
CO2019014647A2 (es) Composiciones inmunogénicas
PL3500287T3 (pl) Kompozycja zawierająca samoorganizujące się peptydy do stosowania do leczenia zapalenia przyzębia i/lub zapalenia tkanek okołowszczepowych
EP3689998A4 (en) Propellant, propellant composition and atomizer
MX385447B (es) Agente antihipertensivo
PL3466403T3 (pl) Zastosowanie monosacharydu do poddziąsłowego i/lub naddziąsłowego czyszczenia zębów
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
MX392976B (es) Composiciones que comprenden cepas bacterianas.
EA201990064A1 (ru) Противомалярийные композиции и варианты их применения
MX383386B (es) Nuevos inhibidores de braf y uso de los mismos para el tratamiento de reacciones cutáneas.
EP3893885A4 (en) ACTIVE TESTOSTERONE ESTER DERIVATIVES, COMPOSITIONS AND USES THEREOF
MX376853B (es) Odorante osmanthus.
PL420249A1 (pl) Kompozycja do leczenia czerniaka u ludzi
MA45718A (fr) Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
HUE057646T2 (hu) Tirotricin testszag kezelésében és/vagy megelõzésében történõ alkalmazásra, és erre szolgáló készítmények
CO2020003134A2 (es) Moduladores de la expresión de enac
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MA47198A (fr) Combinaison d'un inhibiteur de mcl-1 et d'un composé de taxane, ses utilisations et compositions pharmaceutiques la comprenant
MX2020005682A (es) Extracto de helichrysum gymnocephalum para el tratamiento y/o la prevencion de dermatosis inflamatorias.
UA130333C2 (uk) Композиції, які містять кромогліцієву кислоту, для лікування дерматиту